Method of preventing postpartum inflammatory diseases of uterus and mammary glands of cows

FIELD: veterinary medicine.

SUBSTANCE: method comprises intramuscular administration in the body of the medicinal drug of antioxidant action prior to anticipated calving twice. The first administration is performed 50÷60 days before. The second administration is carried out 15÷20 days prior to anticipated calving. The medicinal drug is used as immunofan which is administered in a dose of 4÷5 ml per animal.

EFFECT: invention is highly effective for prevention of postpartum inflammatory diseases of uterus and mammary gland.

3 tbl, 1 ex

 

The invention relates to veterinary, in particular to veterinary obstetrics, and can be used for prevention of postpartum inflammatory diseases of the uterus and breast cancer.

Postpartum inflammatory diseases of the reproduction system (uterus - the endometrium and the breast - mastitis) are recorded at 40-50% or more of lactating cows and are critical veterinary, technological, environmental and social problems in modern dairy cattle breeding, as they are one of the main causes of declining fertility and milk production of animals, as well as sanitary-hygienic and technological qualities of milk.

The development and nature of the pathological processes in the organs of reproduction of cows after birth is determined by the condition of their hormonal, metabolic, antioxidant and immune homeostasis, and virulence of infectious agents, penetrating into the birth canal and mammary gland. Therefore, the basis of prevention of postpartum diseases in cows is the use of pharmacological agents, hormonal and metabolic homeostasis and functional activity of immune protection system.

Known methods of prevention birth and postnatal inflammatory diseases in cows, providing for the introduction�them their tissue preparations [RU 2178705 C2, AT 35/50, 27.01.2002; EN 2201758 C2, AC 35/48, AR 15/00, 10.04.2003], ligfola [RU 2252030 C1, AK 35/78, AR 15/00, 20.05.2005].

Their biological General stimulating action is directed to the correction of metabolic processes and indirectly to increase the immunological reactivity. However, the extent of this impact on the immune defense system and accordingly the preventive effect of these drugs is insufficient.

As a prototype the selected method of preventing preeclampsia and its complications in cows and heifers, including intramuscular administration of selemag, injection is carried out at a dose of 5 ml per 100 kg body weight, twice: for and 25-30 55-60 days prior to calving [RU 2467722 C1, A61D 7/00, 27.11.2012].

Preventive effect of selenium is associated with drug effects on antioxidant defense system, General homeostasis is one of the pathogenesis of inflammatory diseases. The effect of such drugs only indirectly affects the immune system - the main link in the mechanisms of the response of organism to the infectious agent that causes the development of inflammation. Therefore, the effectiveness of this method of prevention is not high enough.

The technical result of the invention - expanding Arsenal of methods of prevention of postpartum inflammatory diseases of the uterus and of the mammary gland and increased�e their effectiveness.

The technical result is achieved in that in the method of prevention of postpartum inflammatory diseases of the uterus and mammary gland in cows, including intramuscular injection into the body of a medicinal product antioxidant action prior to calving twice, and the first infusion is carried out for 55÷60 days, according to the invention, the second injection is carried out for 15÷20 days prior to calving, and as a drug used immunofan, which is administered at a dose of 4÷5 ml per animal.

Immunofan - synthetic Hexapeptide, have direct immunomodulatory, detoxification, antiviral and antibacterial action [guidelines for the evaluation and correction of the immune status of the animals. - Voronezh, 2005. - S. 79-81].

The response of the organism to the drug develops within 2-3 hours after injection and lasts up to four months. In the first three days increases the activity of the antioxidant defense system and comes normalization of lipid peroxidation. Subsequently there is a restoration of disorders of cellular and humoral immunity.

The method is carried out by two-fold intramuscular introduction of cows for 55-60 days and 15-20 days prior to calving imunofana at a dose of 4-5 ml per animal.

The essence FPIC�BA is illustrated by examples.

Example 1. In the experience turned 60 down-calving cows, which distribute into three groups. Cows of the first group (n=16), respectively and 15-20 55-60 days prior to calving was intramuscularly injected with 4 ml of Imunofan, the cows of the second group (n=19) at the same time intramuscularly injected the drug selenium - Salamah at a dose of 5 ml per 100 kg body weight. These animals served as positive control. Cows of the third group (n=25) of the drugs were prescribed and they constituted the negative control group. Evaluation of the efficacy of the preparations were based on clinical examination of animals, morphobiochemical, hormonal analysis of blood for 7-10 days before calving and clinical control over the nature of the flow of the postpartum period.

Data for the study of hematological and immunological status of cows is presented in table 1, from which it follows that shifts in metabolic homeostasis in cows under the influence of the antioxidant drug Salamah and immunomodulating drug Immunofan have a common direction: the normalization of peroxide oxidation and protein metabolism, increasing the level of humoral and cellular protection, reduction of endogenous intoxication. However, the degree of response of an organism of cows introduced to various drugs. So, in the group of cows treated with Selenium, in comparison with control animals, pok�indicators of blood concentrations of total protein decreased by 4.4%, malondialdehyde (MDA) - 45.2%, creatinine - 12.6% the activity of alanine aminotransferase (Alat) - 28.8%, aspartate aminotransferase (AST) - 10.7%, gamma-glutamyl transferase (GGT) - 19.9%. The urea content increased by 11.8%, triiodothyronine (T3) - 32.8%, cortisol - 2.5 times. Bacterial activity of blood serum (BASQUE) increased by 22.8%, the content of immunoglobulins - 21.5%, white blood cells, which is 6.7% while improving their neutrophil forms of 9.7%, monocytes - 5.0% and the reduction of eosinophils by 25%. Whereas in cows treated with immunogenum, the change in the indicators squirrel was 9.4%, urea - 32,3%, AST - 18,8%, GGT - 52.%, T3was 68.8%, immunoglobulins - 43%, the BASQUE of 72.9%, the content of leukocytes and 20.3%, neutrophils - 15,4%, monocytes - 25,0% and eosinophils was 46.3%, the concentration of MDA decreased 42.1%, creatinine - by 10.7%. The last two indicators were close to the animals of the first group.

Table 1
Immunobiochemistry and hematological status of cows in the appointment of selemag and Imunofan
IndicatorControl without the use of drugsWith the use of selemagExperience (statement� method)
Total protein, g/l74,4±1,8971,1±1,7970,0±1,52
Urea, mmol/l1,70±0,161,90±0,252,25±0,16
Creatinine, mm/l107,5±94,0±0,5894,0±0,5896,0±5,80
Alat, U/l21,2±2,6715,1±1,9820,6±3,69
AST, U/l63,7±4,8956,9±1,8552,1±3,35
GGT, U/l14,6±0,9711,7±1,917,0±2,59
HMM, µm/l3,23±0,241,77±0,281,87±0,12
T3nm/l2,44±0,213,24±0,384,12±0,60
Cortisol, nm/ml3,31±0,478,26±1,815,09±1,05
Total immunoglobulins, g/l20,0±0,4824,3±0,0228,6±0,73
The BASQUE %53,8±8,9366,1±6,2093,0±0,84
Leukocytes, 109l7,4±0,617,9±0,078,9±0,17
Neutrophils, %38,4±4,2342,0±2,1244,3±0,85
Eosinophils, %8,4±2,506,3±2,364,5±1,55
Monocytes, %4,0±0,554,2±0,375,0±1,08

Therefore, the effect of Imunofan on the normalization of peroxide oxidation and reduction of endogenous intoxication level was almost similar to the action of Selemag and improve the immune level of protection based on indicators of changes in the content of immunoglobulins, the BASQUE and leukocytes, surpassed it in 2-3 times.

Injection of cows Imunofan provide greater�communication not only their overall immune status, but local immune protection of the genital organs, as evidenced by the change in vaginal microbiocenosis (PL.2).

Table 2
Indicators of vaginal microbiocenosis of cows in the appointment of selemag and Imunofan
IndicatorControl without the use of drugsWith the use of selemagExperience (the claimed method)
Lactobacilli, %80,060,0100,0
Bifidobacteria %60,080,0100,0
Bifidobacteria, titre10-2,010-2,2104,75
Enterobacteria, titre10-3,010-3.110-1,3
Microscopic fungi %60,020,0-
Sensitive�th microflora to antibacterial drugs, %21,923,846,9

In the appointment of selemag revealed no pronounced changes in the composition of the microbiota, with the exception of reducing contamination of the vagina mushrooms 3 times. The use of Imunofan ensured the enhancement of colonization resistance of the genital organs, as evidenced by the decrease in the vaginal mucus caption enterobacteria 2.3 times, complete disappearance of microscopic fungi and increase the titer of bifidobacteria in 2.4 times, while reducing the resistance facultative obligate microflora and its sensitivity to antibacterial drugs in 2.1 times.

Data for clinical analysis, state of the genital organs of cows after calving are presented in table 3.

Table 3
The influence of the drugs Salamah and immunofan on the manifestation of postpartum diseases in cows
IndicatorControl without the use of drugsWith the use of selemagExperience (the claimed method)
The number of cows25 1916
Registered endometritis: number %
840
32,021,10
Preventive effect %68,078,9100
Registered
mastitis:842
Number32,021,112,5
%
Preventive effect %68,078,987,5

Table 3 shows that the processing of the down-calving cows Selenium ensured a reduction in the incidence of cows with endometritis and mastitis�m 1.52 times.

Two-fold intramuscular introduction of cows Imunofan (the claimed method) provided a reduction in the incidence of mastitis cows after giving birth at 2.56 times and in 100% of cases profractional manifestation of endometritis.

The claimed method of prevention of postpartum inflammatory diseases of the uterus and breast cancer, in comparison with the existing, more effective prevention of diseases of the genital tract in 1.27 times and breast cancer - in 1,11 times.

The method of prevention of postpartum inflammatory diseases of the uterus and mammary gland in cows, including intramuscular injection into the body of a medicinal product antioxidant action prior to calving twice, and the first introduction is performed at 50÷60 days, characterized in that the second injection is carried out for 15÷20 days prior to calving, and as a drug used immunofan, which is administered at a dose of 4÷5 ml per animal.



 

Same patents:

FIELD: veterinary medicine.

SUBSTANCE: method comprises intramuscular administration of the tylosin-containing preparation at a dose of 0.05 ml/kg body weight once a day for 3-4 days in all forms of mastitis. The tylosin-containing preparation is used as the preparation of the following composition, wt %: colistin sulphate - 4.0-6.0; tylosin base - 4.0-6.0; benzyl alcohol - 4.0; water for injection - 15.0; 1,2-propylene glycol - 100.0%.

EFFECT: use of the claimed invention enables to improve the therapeutic efficacy of treatment of mastitis.

3 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and concerns a stable composition of nanostructured Sildenafil inhibiting cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDEV) containing a nanostructured Sildenafil base or its pharmaceutically acceptable salts having an average particle size of less than approximately 500nm, a stabilising agent, wherein the composition is prepared in a microfluidics-based continuous-flow tank reactor, and the composition possesses a semi-amorphous structure. The group of inventions also concerns a method for preparing the composition of nanostructured Sildenafil; using the above composition for preparing the pharmaceutical composition for treating male or female sexual dysfunction and pulmonary arterial hypertension.

EFFECT: group of inventions provides the improved solubility of the composition.

8 cl, 11 ex, 14 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of structural formula (I), which can be used for treating diseases mediated by an androgen receptor. In formula (I), R1 means (C2-6)alkyl, (C1-6)alkyloxy, -S(O)m-(C1-6)alkyl, (C1-6)fluoroalkyl, CN or halogen, R2 and R3 are identical or different and mean a hydrogen atom or (C1-9)alkyl, R4, R5, R6, R7 are identical or different and mean a hydrogen or halogen, X means CH or N, Y means either a nitrogen atom, or a carbon atom substituted by (C1-6)alkyl, (C1-6)alkyloxy, (C1-6)fluoroalkyl, a hydrogen atom or halogen; m is equal to 0, 1 or 2.

EFFECT: invention refers to using the compounds for preparing a therapeutic agent for preventing and/or treating hirsutism, androgenetic alopecia, hypertrichosis, atopic dermatitis, disordered sebaceous gland, such as hyperseborrhea, acne, greasy skin or seborrheic dermatitis.

8 cl, 2 tbl, 26 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises intravaginal administration of probiotic preparation "Giprolam" (Lactobacillus fermentum 44/1 and Lactococcus lactis subsp. Lactis 574). "Giprolam" is administered for 5-7 days prior to calving daily at a dose of 100 cm3.

EFFECT: use of the claimed invention promotes to maintain the amount of lactobacilli and bifidobacteria at the physiological level, prevents the colonisation of the genital tract with potentially pathogenic microflora and prevents the occurrence of postpartum infections.

6 tbl, 2 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises the combined use of the tissue preparation on the 1, 3 and 5 days of treatment, and 15% solution of ASD-2f on tetrahydrovit at a dose of 10 ml intramuscularly on the 2, 4 and 6 days of treatment. The tissue preparation is used as biogenic stimulator aminoseleton which is administered subcutaneously into the upper third of the neck in increasing dose of 40-45-50 ml.

EFFECT: method is highly effective for treatment of subclinical mastitis in lactating cows.

3 tbl, 1 ex

FIELD: veterinary medicine.

SUBSTANCE: chemotherapeutic agent is used as N,N-dimethylamino-propylamides of fatty acids of the formula 1 which are used in the form of salts with pharmacologically acceptable acids.

EFFECT: use of the claimed invention is highly effective for treatment of animals with postpartum endometritis.

4 tbl, 2 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises the use of chemotherapeutic agents. The chemotherapeutic agent is used as N,N-dimethylamino-propylamides of fatty acids of the formula 1 which are used in the form of salts with pharmacologically acceptable acids.

EFFECT: use of the claimed invention is highly effective for treatment of endometritis in animals.

4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and medical equipment, namely to obstetrics and gynaecology, and can be used for the local treatment of inflammatory diseases of the uterine cavity. The method is implemented by inserting a waveguide of a presented device in a protection enclosure into the uterine cavity. A taper base of a narrow portion of the enclosure leans on an external orifice of the cervical uterus to prevent accidental perforation of the uterus. An infusion system regulator is used to set the spray supply of a therapeutic solution into an irrigation canal of the ultrasonic device. Thereafter ultrasonic vibrations are generated, and the uterine cavity is treated with the sounded therapeutic solution. The exposure length is 3-5 minutes at the ultrasonic vibration frequency of 25 kHz, infusion rate approximately 100-150 ml/min. The total infusion volume is not less than 300 ml. The ultrasonic treatment enables providing the continuous outflow of the uterine discharge. The device comprises an US generator, an acoustic assembly, the waveguide with the protection enclosure, the infusion system for the therapeutic solution supply. The acoustic assembly and waveguide comprises the irrigation canal. A working tip of the waveguide represents a short cylinder having a diameter greater than the rest portion. The irrigation canal of the waveguide has a diameter of 2 mm. The protection metal thin-wall enclosure has a crimped distal end and drain holes and represents two cylindrical elements of various diameters connected by a taper junction with milled grooves arranged so that to enable the fluid access to the working tip cylinder, the length of which makes no more than 3 mm.

EFFECT: inventions provide the effective cleansing of the uterine cavity from infected and necrotised tissues with improved comfort and safety of the procedure with using no endoscopic equipment, cervical dilation manipulations and uterine pre-probing.

2 cl, 3 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, particularly to an agent for treating and preventing endometritis in animals. The substance of the invention consists as follows. Novocaine 0.5 g is dissolved in distilled water 1 l, and the following preparations are dissolved in a solution of Novocaine 250 mg: powdered metronidazole 4.0 g is dissolved in Novocaine 250 ml; powdered ciprofloxacin 2.0 g is dissolved in Novocaine 250 ml; powdered Doxycycline 1.0 g is dissolved in Novocaine 250 ml; powdered tavegil 2.5 g is dissolved in Novocaine 250 ml; all the ingredients are combined to prepare the agent in an amount of 1 litre for treating and preventing endometritis in animals.

EFFECT: invention provides the pronounced anti-inflammatory and antimicrobial effect of a broad spectrum of action combined with reducing the body response to histamine, relieving smooth muscle spasm and reducing capillary penetration.

5 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary and is intended for treatment and prevention of postpartum acute mastitis in cows. Medication contains antimicrobial, anti-inflammatory preparations and distilled water. Medication additionally contains licorice root. As antimicrobial preparation it contains metronidazole. as anti-inflammatory preparation it contains ciprofloxacin, with the following component ratio, g/l: licorice root 80-85 g; metronidazole 3.5-4.0 g; ciprofloxacin 2.0-2.5 g; distilled water - the remaining part.

EFFECT: application of claimed medication provides expressed antimicrobial and anti-inflammatory effect with simultaneous reduction of organism's response to histamine, release of spasm of smooth muscles and reduction of permeability of capillaries.

4 tbl, 10 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to dermatovenerology and may be used to treat the infections caused by human papilloma viruses, implemented through interleukin-18 induction. For this purpose, the inducer is presented by medicines of the peptide alloferon using the mechanical removal of any type of papilloma formation. The inducer is presented by injections of the preparation 'Allokin-alpha lyophilisate for solution for subcutaneous administration'; the therapeutic course is 3 injections every second day, and the course may be repeated. The inducter is presented by alloferon suppositories. The inducers are presented by the ointments containing alloferon.

EFFECT: method provides the effective treatment ensured by the stimulation of natural immunity through interleukin-18 induction.

4 cl, 3 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to combinations of peptides in each case with the same sequence length (SEQL) which can be prepared in a stable reproducible quality and quantity of a mixture (A) containing a number of x amino acid with protected acid groups or a number of z peptides with the acid groups protected by the protective groups and the activated amino groups, with the amino acids in the mixture (A) found in a specific molar ratio, and a mixture (B), containing a number of y amino acids with the amino groups protected by the protective groups, with a molar ratio of the amino acids of the mixture (B) being the same as the molar ratio of the amino acids of the mixture (A), and the number x=y, and x is a figure from 11 to 18.

EFFECT: new combinations of the peptides are presented.

13 cl, 2 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biochemistry. A biomass of the gram-negative bacteria Salmonella typhi fam. Enterobacteriacea is prepared. A cell wall peptidoglycane (CWP) of the bacteria is recovered by biomass extraction in 45% aqueous phenol at temperature 70-90°C or in aqueous solution of ionic or non-ionic detergents at temperature 37-100°C. That is followed by preparative enzymatic hydrolysis for insoluble CWP cleavage with the use of lysozyme at pH 4.5 - 8.9 and temperature 10 - 37°C. Simultaneously, a pharmacologically acceptable mixture of substances is removed by dialysis from the reaction mixture with the use of semipermeable membranes for ultrafiltration with cut-off size up to 5 kDa. The mixture of substances is also recovered by means of column gel-chromatography, particularly preparative gel chromatography on Sephadex or TSK gel columns. The end product yield is 320 mg.

EFFECT: method enables producing the pharmacologically acceptable mixture of substances containing the following ingredients: β-N-acetyl-D-glucosaminyl-(1→4)-N-acetyl-D-muramoyl-(L-alanyl-D-isoglutaminyl-meso-diaminopimelic acid) (GMtri); β-N-acetyl-D-glucosaminyl-(1→4)-N-acetyl-D-muramoyl-(L-alanyl-D-isoglutaminyl-meso-diaminopimeloyl-D-alanine) (GMtetra); and GMtetra dimer (diGMtetra) wherein a bond of monomer residues of GMtetra is enabled by a carboxyl group of terminal D-alanine of one GMtetra residue and ω-aminogroup of meso-diaminopimelic acid of the other GMtetra residue with the coupled tetrapeptide resides positioned in various polysaccharide chains.

4 cl, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely immunology, and may be used for increasing proliferative activity of peripheral blood lymphocytes. That is ensured by applying a synthetic agent in a medicinal base. The synthetic agent is presented by synthetic peptides having the structure LYS GLY PRO LEY THR NLE NLE ALA SER HIS TYR LYS GLN HIS CYS PRO and THR NLE NLE ALA SER HIS TYR LYS GLN HIS CYS PRO, of molecular weight 1794 to 1397 Da, in the concentrations of 10-4 to 10-5 mg/ml of the medicinal base which is presented by physiologic saline to be applied once a day.

EFFECT: use of the given method enables higher proliferative activity of lymphocytes required for pathogenetic therapy of the diseases.

1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine and pharmacology, and represents the use of a pharmaceutically acceptable salt of alpha-ketoglutaric acid for preparing a pharmaceutical composition for treatment or prevention of cartilage diseases in response to weight loss and/or nutritional disorder, poor nutrition, gastrectomy, partial gastrectomy or gastric ligation.

EFFECT: invention provides effective relief and management of articular pain and arthritis.

20 cl, 8 tbl, 3 dwg

FIELD: medicine.

SUBSTANCE: invention refers to experimental medicine and veterinary science. The invention disclosed unexpected administration of Pro-Gly-Pro peptide as an intranasal agent in prevention and treatment of gastric ulcer in rats.

EFFECT: invention provides higher effectiveness and simplified administration of the agent.

5 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention concerns veterinary science. The invention discloses administration of Arg-Pro-Gly-Pro tetrapeptide as an agent for prevention and treatment of viral diseases. A pharmaceutical composition for prevention and treatment of viral diseases contains an aqueous solution of Arg-Pro-Gly-Pro tetrapeptide in concentration 0.1-1 % and Nipagin in a certain relation of ingredients. A method for prevention of viral diseases involves intranasal, oral or intraperitoneal introduction of said pharmaceutical composition in a dose 0.2-5 mg a day per a mouse for 2 days. A method for treatment of viral diseases involves intranasal, oral or intraperitoneal introduction of said pharmaceutical composition in a dose 0.2-5 mg a day per a mouse for 3 days.

EFFECT: invention enables extending the range of antiviral drugs, providing higher clinical and preventive effectiveness in viral infections, reducing drug cost.

4 cl, 4 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a peptide copolymer containing lysine, alanine, tyrosine and glutaminic acid residues in ratio of 0.4-0.45:0.3-0.36:0.09-0.11:0.14-0.18, including its acid addition salt - acetate, and having average molecular weight in the interval 8.7-14.5 kDa, which can be used in a pharmaceutical composition for preparing a medicinal agent against multiple sclerosis, particularly medicinal agent Glatiramer acetate. The peptide copolymer is obtained through copolymerisation of N-carboxyanhydride of Nε-trifluoroacetyl-L-lysine and/or N-carboxyanhydride of Nε-benzyloxycarbonyl-L-lysine with N-carboxyanhydrides of L-alanine, gamma-O-benzyl-L-glutaminic acid and L-tyrosine with an initiator diethylamine in a medium of aprotic solvents dioxane or tetrahydrofuran or mixtures thereof. Benzyl type protective groups are removed from lysine and glutaminic acid residues using a solution of hydrogen bromide in acetic acid with a catalytic amount of water, and volatile amines diethylamine or methylamine in form of their aqueous solution are used to remove protective trifluoroacetyl groups from lysine residues.

EFFECT: method enables control of such properties of the product as average molecular weight and amino acid composition.

3 cl, 7 ex

FIELD: medicine; veterinary science.

SUBSTANCE: administer an immunopotentiator to females of mammals into a lactemia initial stage. The immunopotentiator immunifan is administered to lactating females in a dose of mass of a body of 0.0006-0.0008 mg/kg. The immunopotentiator amyxine is administered to lactating females in a dose of mass of a body of 0.0017-0.0018 g/kg.

EFFECT: increase of content of immunoglobulins, leucocytes and mononuclear cells in milk of lactating animals.

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with inhibiting the growth of host's cerebral tumors. It deals with introducing therapeutically efficient quantity of integrin αv antagonists being cyclo(Arg-Gly-Asp-D-Phe-[N-Me]-Val). The innovation enables to considerably inhibit cerebral oncogenesis in vivo, moreover, despite antiangiogenesis, due to induction of direct lethality of tumor cells.

EFFECT: higher efficiency of inhibition.

9 dwg, 2 tbl

FIELD: medicine, oncology.

SUBSTANCE: the present innovation deals with inhibiting the growth of host's cerebral tumors. It deals with introducing therapeutically efficient quantity of integrin αv antagonists being cyclo(Arg-Gly-Asp-D-Phe-[N-Me]-Val). The innovation enables to considerably inhibit cerebral oncogenesis in vivo, moreover, despite antiangiogenesis, due to induction of direct lethality of tumor cells.

EFFECT: higher efficiency of inhibition.

9 dwg, 2 tbl

Up!